Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.
Initiating therapy with a combination of immune modulators (IM) and antitumour necrosis factor (anti-TNF) agents appears to reduce the incidence of therapeutic ineffectiveness in patients with Crohn’s disease (CD) but not those with ulcerative colitis (UC), a recent study has found.
Besifovir dipivoxil maleate has antiviral efficacy against chronic hepatitis B that is similar to that of tenofovir disoproxil fumarate but with a lower impact on bone and renal safety, as shown in the results of a phase III trial involving Asian patients.
Persistence to treatment with a tumour necrosis factor (TNF)‐α inhibitor for inflammatory bowel disease (IBD) appears to be lower among female than male patients, as reported in a recent study. Treatment discontinuation is driven mainly by side effects, the rate of which being higher in women than in men.
Dr Andrew Ong, a consultant at the Department of Gastroenterology & Hepatology, Singapore General Hospital, explains to Roshini Claire Anthony the challenges in diagnosing and treating irritable bowel syndrome (IBS).
Marketplace introduction of the antitumour necrosis factor (anti-TNF) therapy infliximab seems to have little appreciable impact so far on the rates of inflammatory bowel disease (IBD)-related hospitalizations or intestinal resections among patients with Crohn’s disease (CD) or ulcerative colitis, despite robust penetration of the drug in the CD population, as reported in a recent study from Canada.
The combination of TAS-118 and oxaliplatin led to significantly greater survival compared with the S-1 and cisplatin combination in patients with metastatic or recurrent HER2-negative gastric cancer, the phase III SOLAR* study showed.
Disease-free survival (DFS) at 3 years was comparable between patients with locally advanced gastric cancer who underwent laparoscopic distal gastrectomy and open distal gastrectomy, pointing to the noninferiority of the laparoscopic procedure to the open one, according to the CLASS-01* study.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.
There appears to be an increase in inpatient incidence and mortality for gastrointestinal bleeding (GIB) related to percutaneous coronary intervention (PCI), particularly among older patients, a recent study has found.